Skip to main content
Cybin Inc. logo

Cybin Inc. — Investor Relations & Filings

Ticker · HELP ISIN · CA23256X4075 NEO Manufacturing
Open in API
Filings indexed 670 across all filing types
Latest filing 2026-05-01 Regulatory Filings
Country CA Canada
Listing NEO HELP

About Cybin Inc.

http://www.cybin.com

Cybin Inc. is a clinical-stage biopharmaceutical company specializing in breakthrough neuropsychiatry, committed to developing next-generation therapeutics to revolutionize mental healthcare. The company utilizes proprietary drug discovery platforms to innovate Novel Serotonergic Agonists (NSAs)—synthetic molecules designed to activate serotonin pathways and promote neuroplasticity—paired with precision drug delivery systems. A core technological differentiator is the use of deuteration technology to create treatments with consistent delivery and commercial scalability. Cybin maintains a robust intellectual property portfolio, including over 100 granted patents and 250 pending applications, supporting its active drug programs, such as CYB004, currently in Phase 2 clinical trials for the treatment of Generalized Anxiety Disorder. The mission is to provide treatments designed to foster durable improvements in mental health.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2026-05-01 English
News release - English.pdf
Regulatory Filings
2026-04-30 English
News release - English.pdf
Regulatory Filings
2026-04-28 English
News release - English.pdf
Board/Management Information Classification · 80% confidence The document is a company press release announcing the addition of two new members to Helus Pharma’s Scientific Advisory Board. This is an announcement of changes in the company’s board-level advisory structure (governance/management appointments). It does not present financial results, call transcripts, or regulatory filings, but rather changes in the advisory board composition, fitting most closely under “Board/Management Information” (MANG).
2026-04-23 English
News release - English.pdf
Board/Management Information Classification · 85% confidence The document is a corporate press release announcing the appointment of two new members to the Scientific Advisory Board. This is an announcement of changes in the company's advisory/management body. Therefore, it falls under Board/Management Information (MANG).
2026-04-23 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release dated April 20, 2026, from Helus Pharma expressing support for a White House Executive Order related to psychedelic research and regulatory pathways for mental health conditions. It discusses the company's clinical development programs, regulatory designations, and forward-looking statements about the business and market environment. There are no financial statements, detailed financial results, or regulatory filings such as 10-K, 10-Q, or audit reports. The content is primarily a corporate announcement about policy support and business outlook, typical of a general regulatory or corporate news release. It does not fit into categories like earnings release, annual report, or management discussion. It is not a report publication announcement since it does not mention the release or availability of a report. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements and regulatory news that do not fit other categories.
2026-04-20 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.